Sandbox : anmol

Jump to navigation Jump to search

Hyperparathyroidism Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Hyperparathyroidism from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Sandbox : anmol On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Sandbox : anmol

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Sandbox : anmol

CDC on Sandbox : anmol

Sandbox : anmol in the news

Blogs on Sandbox : anmol

Directions to Hospitals Treating Hyperparathyroidism

Risk calculators and risk factors for Sandbox : anmol

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Anmol Pitliya, M.B.B.S. M.D.[2]

Classification

Classification of hyperparathyridism
Features Primary hyperparathyroidism Secondary hyperparathyroidism Tertiary hyperparathyroidism
Pathology Hyperfunction of parathyroid cells due to hyperplasia, adenoma or carcinoma. Physiological stimulation of parathyroid in response to hypocalcaemia. Following long term physiological stimulation leading to hyperplasia.
Cause
Associations May be associated with multiple endocrine neoplasia. Usually due to chronic renal failure or other causes of Vitamin D deficiency. Seen in chronic renal failure.
Serum calcium High Low/Normal High
Serum phosphate Low/Normal High High
Management Usually surgery if symptomatic. Cincacalcet can be considered in those not fit for surgery. Treatment of underlying cause. Usually cinacalcet or surgery in those that don't respond.

Symptoms

  • Clinical symptoms depends on two features:[1]
    • Acuteness of hypocalcemia
    • The absolute level of serum calcium
  • Patients presents dramatically and tends to have more symptoms if there is an acute drop in serum calcium compared to patients with chronic hypocalcemia.[2]

Common symptoms

Common symptoms of hypoparathyroidism include:[1][3]

  • Tetany (hallmark of acute hypocalcemia)
  • Paresthesia in fingertips, toes, perioral area
  • Carpopedal spasms
  • Circumoral numbness
  • Abdominal pain
  • Biliary colic
  • Dysphoria
  • Fatigue
  • Muscle cramps
  • Myoclonic jerks
  • New onset seizure due to hypocalcemia or worsening of seizures
  • Painful menstruation

Less common synptoms

Less common symptoms of hypoparathyroidism include:[1][3]

  • Cognitive impairment
  • Decreased concentration
  • Hoarseness (due to laryngospasm)
  • Neuromuscular irritability
  • Palpitations due cardiac dysarrhythmias
  • Personality disturbances and/or mood changes
  • Symptoms of acute cardiomyopathy
  • Wheezing and dyspnea (due to bronchospasm)
  • Electrocardiographic changes that mimic myocardial infarction, or congestive heart failure (decreased cardiac contractility is related to low serum calcium and possibly parathyroid hormone deficiency, as there are PTH receptors in cardiac myocytes).[4]


  • Cardiac manifestations
    • prolonged QT interval and T-wave alternans, , and congestive heart failure due to decreased cardiac contractility related to low serum calcium and possibly PTH deficiency, as there are PTH receptors in cardiac myocytes.

Differential Diagnosis

Differential diagnosis of hyperparathyroidism on the basis of hypocalcemia
Disorders Mechanism of hypocalcemia Laboratory findings
Serum PTH Serum Calcium Serum Phosphate Other findings
Hypoparathyroidism
  • There is deficiency of parathyroid hormone in hypoparathyroidism.
  • Deficiency of parathyroid hormone causes body to decrease:
    • Reabsorption of calcium from bone.
    • Excretion of phosphate.
    • Reabsorbtion of calcium from distal tubules.
    • Vitamin D mediated absorption of calcium from intestine.
  • 1,25 Dihydroxy vitamin D
  • Normal urinary cAMP
  • Normal urinary phosphate
Pseudohypoparathyroidism [5][6][7] Type 1a
  • 1,25 Dihydroxy vitamin D
  • Urinary cAMP
  • Urinary phosphate
Type 1b
  • 1,25 Dihydroxy vitamin D
  • Urinary cAMP
  • ↓ Urinary phosphate
Type 1c
  • 1,25 Dihydroxy vitamin D
  • Urinary cAMP
  • Urinary phosphate
Type 2
  • 1,25 Dihydroxy vitamin D
  • Normal urinary cAMP
  • Urinary phosphate
Pseudopseudohypoparathyroidism Normal Normal Normal --
Hypomagnesemia[8][9]
  • Decreased parathyroid hormone (PTH) secretion
  • Skeletal resistance to PTH
Inappropriately Normal/ --
  • serum magnesium
  • /Normal serum potassium
Hypoalbuminemia
  • Majority of calcium in blood is bound to albumin. So when there is a decrease in concentration of albumin due to any condition, there is a relative hypocalcemia as well.
-- --
  • serum albumin
  • Normal albumin-corrected serum total calcium
  • Normal ionised calcium
Hypovitaminosis D
  • Decrease in vitamin D meediated calcium absorption from gut.
/Low-normal
  • 25 Hydroxy vitamin D
Chronic kidney disease /Normal
  • Glomerular flitration rate

References

  1. 1.0 1.1 1.2 Abate EG, Clarke BL (2016). "Review of Hypoparathyroidism". Front Endocrinol (Lausanne). 7: 172. doi:10.3389/fendo.2016.00172. PMC 5237638. PMID 28138323.
  2. Tohme JF, Bilezikian JP (1993). "Hypocalcemic emergencies". Endocrinol. Metab. Clin. North Am. 22 (2): 363–75. PMID 8325292.
  3. 3.0 3.1 Cooper MS, Gittoes NJ (2008). "Diagnosis and management of hypocalcaemia". BMJ. 336 (7656): 1298–302. doi:10.1136/bmj.39582.589433.BE. PMC 2413335. PMID 18535072.
  4. Kimura S, Yoshioka K (2014). "Parathyroid hormone and parathyroid hormone type-1 receptor accelerate myocyte differentiation". Sci Rep. 4: 5066. doi:10.1038/srep05066. PMC 4052750. PMID 24919035.
  5. Levine MA (2012). "An update on the clinical and molecular characteristics of pseudohypoparathyroidism". Curr Opin Endocrinol Diabetes Obes. 19 (6): 443–51. doi:10.1097/MED.0b013e32835a255c. PMC 3679535. PMID 23076042.
  6. Mantovani G (2011). "Clinical review: Pseudohypoparathyroidism: diagnosis and treatment". J. Clin. Endocrinol. Metab. 96 (10): 3020–30. doi:10.1210/jc.2011-1048. PMID 21816789.
  7. Lee S, Mannstadt M, Guo J, Kim SM, Yi HS, Khatri A, Dean T, Okazaki M, Gardella TJ, Jüppner H (2015). "A Homozygous [Cys25]PTH(1-84) Mutation That Impairs PTH/PTHrP Receptor Activation Defines a Novel Form of Hypoparathyroidism". J. Bone Miner. Res. 30 (10): 1803–13. doi:10.1002/jbmr.2532. PMC 4580526. PMID 25891861.
  8. Jahnen-Dechent W, Ketteler M (2012). "Magnesium basics". Clin Kidney J. 5 (Suppl 1): i3–i14. doi:10.1093/ndtplus/sfr163. PMC 4455825. PMID 26069819.
  9. Freitag JJ, Martin KJ, Conrades MB, Bellorin-Font E, Teitelbaum S, Klahr S, Slatopolsky E (1979). "Evidence for skeletal resistance to parathyroid hormone in magnesium deficiency. Studies in isolated perfused bone". J. Clin. Invest. 64 (5): 1238–44. doi:10.1172/JCI109578. PMC 371269. PMID 227929.